Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5194020 | 0.98 | GAA (0.70) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL7141724 | 0.88 | TSHR (0.72) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL9843022 | 0.88 | GAA (0.76) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL27425392 | 0.86 | TSHR (0.75) | GAATSHRMAPTRAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL29787366 | 0.86 | TSHR (0.70) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL14544254 | 0.85 | GAA (0.72) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL7813793 | 0.85 | GAA (0.76) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL9671985 | 0.84 | TSHR (0.77) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL7408275 | 0.84 | GAA (0.62) | GAATSHRMAPTRAB9AALDH1A1 | |
| SCHEMBL11384519 | 0.84 | GAA (0.70) | GAATSHRMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294722-B1 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | MERCK EPROVA AG (CH) | 2007-08-01 | — | — | EP | claimed |
| US-8734818-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8734818-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130225648-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225648-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377456-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377456-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120070385-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070385-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | SPECTRUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-8063233-B2 | Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives | SPECTRUM PHARMACEUTICALS INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20050014943-A1 | Methods of synthesis for 9-substituted hypoxanthine derivatives | NEOTHERAPEUTICS, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20040116453-A1 | Synthesis and methods of use pyrimidine analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1303485-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1294722-A2 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | NEOTHERAPEUTICS, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003007963-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEOTHERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002000659-A2 | METHODS OF SYNTHESIS FOR 9-SUBSTITUTED HYPOXANTHINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225648-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | DRD2, DRD4, DRD1 | GAA 560/4885TSHR 3045/4885MAPT 138/4885 |
| US-20120070385-A1 | Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives | HTR2C, HSD11B2, DRD4 | GAA 1517/4885TSHR 3048/4885MAPT 157/4885 |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | ATIC, SLC29A1, ABCG2 | GAA 2435/4885TSHR 1985/4885MAPT 2567/4885 |
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | GAA 130/4885TSHR 2814/4885MAPT 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.